373 related articles for article (PubMed ID: 19473056)
21. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
Loganayagam A; Arenas-Hernandez M; Fairbanks L; Ross P; Sanderson JD; Marinaki AM
Cancer Chemother Pharmacol; 2010 Jan; 65(2):403-6. PubMed ID: 19795123
[TBL] [Abstract][Full Text] [Related]
22. DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia.
Zhao XQ; Cao WJ; Yang HP; Yang XW; Tang P; Sun L; Gao X
Tumour Biol; 2016 Aug; 37(8):10393-402. PubMed ID: 26846104
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
van Kuilenburg AB; De Abreu RA; van Gennip AH
Ann Clin Biochem; 2003 Jan; 40(Pt 1):41-5. PubMed ID: 12542909
[TBL] [Abstract][Full Text] [Related]
24. Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant.
Del Re M; Quaquarini E; Sottotetti F; Michelucci A; Palumbo R; Simi P; Danesi R; Bernardo A
Pharmacogenomics; 2016; 17(1):5-9. PubMed ID: 26651493
[TBL] [Abstract][Full Text] [Related]
25. DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
Božina N; Bilić I; Ganoci L; Šimičević L; Pleština S; Lešnjaković L; Trkulja V
Br J Clin Pharmacol; 2022 May; 88(5):2190-2202. PubMed ID: 34780066
[TBL] [Abstract][Full Text] [Related]
26. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
[TBL] [Abstract][Full Text] [Related]
27. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients.
Sulzyc-Bielicka V; Bińczak-Kuleta A; Pioch W; Kładny J; Gziut K; Bielicki D; Ciechanowicz A
Pharmacol Rep; 2008; 60(2):238-42. PubMed ID: 18443386
[TBL] [Abstract][Full Text] [Related]
28. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
Gross E; Busse B; Riemenschneider M; Neubauer S; Seck K; Klein HG; Kiechle M; Lordick F; Meindl A
PLoS One; 2008; 3(12):e4003. PubMed ID: 19104657
[TBL] [Abstract][Full Text] [Related]
29. Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.
Uzunkoy A; Dilmec F; Ozgonul A; van Kuilenburg AB; Akkafa F
Anticancer Res; 2007; 27(6B):3899-902. PubMed ID: 18225548
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
[TBL] [Abstract][Full Text] [Related]
31. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
[TBL] [Abstract][Full Text] [Related]
32. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.
Froehlich TK; Amstutz U; Aebi S; Joerger M; Largiadèr CR
Int J Cancer; 2015 Feb; 136(3):730-9. PubMed ID: 24923815
[TBL] [Abstract][Full Text] [Related]
33. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.
Savva-Bordalo J; Ramalho-Carvalho J; Pinheiro M; Costa VL; Rodrigues A; Dias PC; Veiga I; Machado M; Teixeira MR; Henrique R; Jerónimo C
BMC Cancer; 2010 Sep; 10():470. PubMed ID: 20809970
[TBL] [Abstract][Full Text] [Related]
34. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.
Deenen MJ; Meulendijks D; Cats A; Sechterberger MK; Severens JL; Boot H; Smits PH; Rosing H; Mandigers CM; Soesan M; Beijnen JH; Schellens JH
J Clin Oncol; 2016 Jan; 34(3):227-34. PubMed ID: 26573078
[TBL] [Abstract][Full Text] [Related]
35. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.
Hsiao HH; Yang MY; Chang JG; Liu YC; Liu TC; Chang CS; Chen TP; Lin SF
Cancer Chemother Pharmacol; 2004 May; 53(5):445-51. PubMed ID: 15132136
[TBL] [Abstract][Full Text] [Related]
36. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
[TBL] [Abstract][Full Text] [Related]
37. Dihydropyrimidine dehydrogenase (DPYD) gene c.1627A>G A/G and G/G genotypes are risk factors for lymph node metastasis and distant metastasis of colorectal cancer.
Zeng J; Wu H; Huang Q; Li J; Yu Z; Zhong Z
J Clin Lab Anal; 2021 Nov; 35(11):e24023. PubMed ID: 34612540
[TBL] [Abstract][Full Text] [Related]
38.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(14):1-186. PubMed ID: 34484488
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
40. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity.
Hamzic S; Schärer D; Offer SM; Meulendijks D; Nakas C; Diasio RB; Fontana S; Wehrli M; Schürch S; Amstutz U; Largiadèr CR
Br J Clin Pharmacol; 2021 Aug; 87(8):3234-3243. PubMed ID: 33491253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
